BlackRock
GANX icon

BlackRock’s Gain Therapeutics GANX Stock Holding History

BlackRock’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558K Buy
274,957
+49,911
+22% +$92K ﹤0.01% 4547
2026
Q1 		$437K Buy
225,046
+15,467
+7% +$33.7K ﹤0.01% 4563
2025
Q4 		$675K Buy
209,579
+93,395
+80% +$249K ﹤0.01% 4412
2025
Q3 		$206K Buy
116,184
+3,677
+3% +$6.2K ﹤0.01% 4676
2025
Q2 		$203K Buy
112,507
+28,100
+33% +$52K ﹤0.01% 4670
2025
Q1 		$161K Sell
84,407
-1,654
-2% -$3.67K ﹤0.01% 4643
2024
Q4 		$186K Buy
86,061
+1,137
+1% +$2.28K ﹤0.01% 4634
2024
Q3 		$151K Buy
84,924
+304
+0.4% +$382 ﹤0.01% 4588
2024
Q2 		$108K Buy
84,620
+9,222
+12% +$23.9K ﹤0.01% 4684
2024
Q1 		$284K Buy
75,398
+47,787
+173% +$198K ﹤0.01% 4517
2023
Q4 		$90.2K Sell
27,611
-314
-1% -$873 ﹤0.01% 4834
2023
Q3 		$91.6K Sell
27,925
-1,099
-4% -$4.17K ﹤0.01% 4869
2023
Q2 		$130K Buy
29,024
+4,246
+17% +$20.7K ﹤0.01% 4840
2023
Q1 		$119K Sell
24,778
-202
-0.8% -$826 ﹤0.01% 4917
2022
Q4 		$78.2K Buy
24,980
+2,079
+9% +$6.5K ﹤0.01% 5116
2022
Q3 		$75K Sell
22,901
-640
-3% -$2.4K ﹤0.01% 5260
2022
Q2 		$85K Buy
23,541
+12,904
+121% +$44.5K ﹤0.01% 5277
2022
Q1 		$43K Sell
10,637
-522
-5% -$2.18K ﹤0.01% 5442
2021
Q4 		$60K Sell
11,159
-317
-3% -$2.19K ﹤0.01% 5377
2021
Q3 		$85K Sell
11,476
-183
-2% -$1.53K ﹤0.01% 5176
2021
Q2 		$116K Buy
+11,659
New +$131K ﹤0.01% 5009

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock's GANX Position: Q2 2026 in Review

BlackRock increased its Gain Therapeutics (GANX) stake by 22% in Q2 2026, buying an estimated $92K and bringing the position to 274,957 shares worth $558K. The position accounts for ﹤0.01% of the portfolio, ranked #4547.

BlackRock first reported a position in GANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $675K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • BlackRock held 274,957 shares of Gain Therapeutics worth $558K as of Q2 2026.
  • BlackRock bought 49,911 Gain Therapeutics shares in Q2 2026, an estimated $92K.
  • Gain Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4547 holding.
  • BlackRock first reported a position in Gain Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • BlackRock's Gain Therapeutics position peaked at $675K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.